OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up
Authors:
- J. SandsJSJ. Sands
- B.C. ChoBCB.C. Cho
- M.-J. AhnMAM.-J. Ahn
- M. ReckMRM. Reck
- J. Bustamante-AlvarezJBJ. Bustamante-Alvarez
- H.-D. HummelHHH.-D. Hummel
- H. AkamatsuHAH. Akamatsu
- M.L. JohnsonMJM.L. Johnson
- E. FelipEFE. Felip
- S. HandzhievSHS. Handzhiev
- I. KorantzisIKI. Korantzis
- H. IzumiHIH. Izumi
- 15 October 2024
- journal article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 19 (10) , S30-S31